210 related articles for article (PubMed ID: 32068436)
1. Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial.
Garg SK; Wernicke-Panten K; Wardecki M; Kramer D; Delalande F; Franek E; Sadeharju K; Monchamp T; Miossec P; Mukherjee B; Shah VN
Diabetes Technol Ther; 2020 Jul; 22(7):516-526. PubMed ID: 32068436
[No Abstract] [Full Text] [Related]
2. Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1).
Garg SK; Wernicke-Panten K; Wardecki M; Kramer D; Delalande F; Franek E; Sadeharju K; Monchamp T; Mukherjee B; Shah VN
Diabetes Technol Ther; 2020 Feb; 22(2):85-95. PubMed ID: 31804851
[No Abstract] [Full Text] [Related]
3. Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized, Open-Label Clinical Trial.
Thrasher J; Polsky S; Hovsepian L; Nowotny I; Pierre S; Bois De Fer B; Bhargava A; Mukherjee B; Garg SK
Diabetes Technol Ther; 2020 Sep; 22(9):666-673. PubMed ID: 31833801
[No Abstract] [Full Text] [Related]
4. Efficacy, Safety, and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin.
Shah VN; Franek E; Wernicke-Panten K; Pierre S; Mukherjee B; Sadeharju K
Diabetes Ther; 2021 Feb; 12(2):557-568. PubMed ID: 33432547
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Switching SAR341402 Insulin Aspart and Originator Insulin Aspart vs Continuous Use of Originator Insulin Aspart in Adults With Type 1 Diabetes: The GEMELLI X Trial.
Shah VN; Al-Karadsheh A; Barnes C; Mandry J; Nakhle S; Wernicke-Panten K; Kramer D; Schmider W; Pierre S; Teichert L; Rotthaeuser B; Mukherjee B; Bailey TS
J Diabetes Sci Technol; 2024 Feb; ():19322968241232709. PubMed ID: 38420944
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of NovoLog in adults with type 1 diabetes: The GEMELLI X trial.
Shah VN; Al-Karadsheh A; Barnes C; Mandry J; Nakhle S; Wernicke-Panten K; Kramer D; Schmider W; Pierre S; Teichert L; Rotthaeuser B; Mukherjee B; Bailey TS
Diabetes Obes Metab; 2024 Feb; 26(2):540-547. PubMed ID: 37880868
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog
Blevins TC; Raiter Y; Sun B; Donnelly C; Shapiro R; Chullikana A; Rao A; Vashishta L; Ranganna G; Barve A
BioDrugs; 2022 Nov; 36(6):761-772. PubMed ID: 36114990
[TBL] [Abstract][Full Text] [Related]
8. Comparative assessment of immunogenicity of recombinant insulin Aspart from BioGenomics and its originator NovoRapid® in adult patients with type 2 diabetes mellitus.
Mishra A; Dongre S; Kulkarni G; Deshmane R; Thappa D; Ghade N; Lona J; Kokatam S; Deo A; Sonar S; Krishnan A
J Endocrinol Invest; 2024 Jun; 47(6):1435-1446. PubMed ID: 38147290
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 1 Diabetes Also Using Insulin Glargine-SORELLA 1 Study.
Garg SK; Wernicke-Panten K; Rojeski M; Pierre S; Kirchhein Y; Jedynasty K
Diabetes Technol Ther; 2017 Sep; 19(9):516-526. PubMed ID: 28722480
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study.
Christofides EA; Puente O; Norwood P; Denham D; Maheshwari H; Lillestol M; Hart T; Nakhle S; Chadha A; Fitz-Patrick D; Sugimoto D; Soufer J; Young D; Warren M; Huffman D; Reed J; Bays H; Arora S; Rizzardi B; Tidman R; Rendell M; Johnson KA
Diabetes Obes Metab; 2024 Jun; 26(6):2412-2421. PubMed ID: 38558508
[TBL] [Abstract][Full Text] [Related]
11. Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes.
Home P; Derwahl KM; Ziemen M; Wernicke-Panten K; Pierre S; Kirchhein Y; Garg SK
Diabetes Technol Ther; 2018 Feb; 20(2):160-170. PubMed ID: 29355435
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of GP40071 compared with originator insulin aspart (NovoRapid
Karonova TL; Mayorov AY; Magruk MA; Zyangirova ST; Grigoryeva IV; Khmelnitski OK; Myshkovets A; Parfenova TM; Mosikian AA; Drai RV
J Comp Eff Res; 2021 Jun; 10(9):763-775. PubMed ID: 33928797
[No Abstract] [Full Text] [Related]
13. Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix Insulin.
Aravind SR; Singh KP; Mogylnytska L; Zalevskaya AG; Matyjaszek-Matuszek B; Wernicke-Panten K; Nguyên-Pascal ML; Pierre S; Rotthaeuser B; Kramer D; Mukherjee B
Diabetes Ther; 2022 Jul; 13(7):1299-1310. PubMed ID: 35650350
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of MYL-1501D vs insulin glargine in patients with type 1 diabetes after 52 weeks: Results of the INSTRIDE 1 phase III study.
Blevins TC; Barve A; Sun B; Ankersen M
Diabetes Obes Metab; 2018 Aug; 20(8):1944-1950. PubMed ID: 29656504
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 2 Diabetes, Also Using Insulin Glargine: SORELLA 2 Study.
Derwahl KM; Bailey TS; Wernicke-Panten K; Ping L; Pierre S
Diabetes Technol Ther; 2018 Jan; 20(1):49-58. PubMed ID: 29232162
[TBL] [Abstract][Full Text] [Related]
16. A single-dose euglycaemic clamp study in two cohorts to compare the exposure of SAR341402 (insulin aspart) Mix 70/30 with US- and European-approved versions of insulin aspart Mix 70/30 and SAR341402 rapid-acting solution in subjects with type 1 diabetes.
Kapitza C; Nosek L; Schmider W; Teichert L; Mukherjee B; Nowotny I
Diabetes Obes Metab; 2021 Mar; 23(3):674-681. PubMed ID: 33236518
[TBL] [Abstract][Full Text] [Related]
17. Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLI M).
Aravind SR; Singh KP; Aquitania G; Mogylnytska L; Zalevskaya AG; Matyjaszek-Matuszek B; Wernicke-Panten K; Nguyên-Pascal ML; Pierre S; Rotthaeuser B; Kramer D; Mukherjee B
Diabetes Ther; 2022 May; 13(5):1053-1071. PubMed ID: 35420397
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic Similarity between Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 and Originator Insulin Aspart Mix 70/30 (NovoMix 30) in Indian Adults with Type 2 Diabetes: GEMELLI M Substudy.
Mohan V; Schmider W; Singh KP; Rotthaeuser B; Mukherjee B; Aravind SR
Indian J Endocrinol Metab; 2022; 26(4):354-361. PubMed ID: 36185965
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of GP40081 (insulin aspart biphasic 30) compared with NovoMix
Drai RV; Mayorov AY; Karonova TL; Parfenova TM; Makarenko IE; Magruk MA; Alpenidze DN; Kovalik VV; Zinnatulina BR; Grigorjeva IV; Andreeva AT
J Comp Eff Res; 2022 Dec; 11(18):1337-1347. PubMed ID: 36511777
[No Abstract] [Full Text] [Related]
20. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
Heller S; Koenen C; Bode B
Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
